{"name":"Stephen G. Kaler","slug":"stephen-g-kaler","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Droxidopa Oral Product","genericName":"Droxidopa Oral Product","slug":"droxidopa-oral-product","indication":"Neurogenic orthostatic hypotension","status":"phase_2"}]}],"pipeline":[{"name":"Droxidopa Oral Product","genericName":"Droxidopa Oral Product","slug":"droxidopa-oral-product","phase":"phase_2","mechanism":"Noradrenergic neuron stimulation","indications":["Neurogenic orthostatic hypotension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxQcTBoZV9xZmhPN0NPSkNESXJlSndfTzFxWm9OaW55V2pZS01DYlp1bXh2V2Ytd0d2RDJzM2pPLWdJMTZ3QXJHdFdLZHRmOThiSHJZdnAwRHBVZ0F3dkFhMGlQUF82Y0REX1dKbUlRdkdoemFiYnpURENqX0tYRTlrOUlHcjRGcDctUm1fdlpLQlloREpJbEQzVEZIN2ltMlNGZTRQZXV0Q3lnalBrMHdheFZqM2dUOS0tblZacHpDM25feXpkNXZFY1RmbjdIMU9ZczFDZjZaY1lXczV0OUVRN3A5Y2l0V1huZXduTExuRGpIRW5ldDhxeUVCRzJfODM3aHg0TUVraUIyOVFLVDZZVncwNHl3TFctOWdGcTZpSUVLOFgwdjEwRHNNNHpWSVRrQnVMaXZNMEhzVlZtbFJRSUpHZmRqbUMtU3VTWkl2aw?oc=5","date":"2025-01-06","type":"regulatory","source":"PR Newswire","summary":"Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease - PR Newswire","headline":"Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Hist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE53eC1FRk93Zm8xaWJ3VU52RWNGdmdEd1JaekpnQ1BxWUwzcXk1MmpFWlNjc3Y5enc1OUVyVFVhOEdKYlhLZGtlMURVaHk3aUFXNjkyZDI0OUZraFNQZDB3?oc=5","date":"2008-02-07","type":"pipeline","source":"NEJM","summary":"Neonatal Diagnosis and Treatment of Menkes Disease - NEJM","headline":"Neonatal Diagnosis and Treatment of Menkes Disease","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":9,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}